Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Date publication

mai 2018

Journal

Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès , Dr AME Shanti

Tous les auteurs :
Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29723417

Résumé

The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is called treatment-free remission (TFR). Knowledge accumulated during the last 10 years justifies moving TFR strategies from research to clinical practice.

Mots clés

chronic myeloid leukemia, clinical practice, recommendations, treatment discontinuation, tyrosine kinase inhibitors

Référence

Cancer. 2018 May 3;: